IRVINE, Calif., Oct. 30, 2006 (PRIMEZONE) -- "In biotechnology and pharmaceutical firms, progress is often measured by trials and approvals, especially those that come as a result of human testing," stated SmallCap Sentinel analyst D.R. Clark. "Research that uses human testing affirms a degree of product confidence and positive results from previous testing. Most companies won't get this far."
"Along these lines, MIV Therapeutics Inc. (OTCBB:MIVT), a leading developer of next-generation biocompatible drug-eluting stents, announced today that it intends to begin the first human implants of a HAp NanoFilm coated stent early in 2007," Clark added. "Clearly, this is an enormous step for MIV in its continual efforts to craft a finer drug-eluting stent."
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies.
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address stents and stent-related companies including MIV Therapeutics, Inc., Angiotech Pharmaceuticals Inc. (Nasdaq:ANPI), Conor Medsystems Inc. (Nasdaq: CONR), and Boston Scientific CP (NYSE:BSX). The report will place specific emphasis on drug eluting stents, their design, application, and imperative need.
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/autoir/mivt_autoir.html
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Companies interested in being featured in SmallCap Sentinel should reach us using the contact info below or sts@marketpathways.com
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen thousand dollars by MIV Therapeutics Inc. for preparation and distribution of this report and other advertising services over a forty-five day period. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies.